In the latest trading session, 14.44 million Cabaletta Bio Inc (NASDAQ:CABA) shares changed hands as the company’s beta touched 2.37. With the company’s most recent per share price at $4.11 changing hands around $0.29 or 7.59% at last look, the market valuation stands at $254.94M. CABA’s current price is a discount, trading about -541.12% off its 52-week high of $26.35. The share price had its 52-week low at $1.76, which suggests the last value was 57.18% up since then. When we look at Cabaletta Bio Inc’s average trading volume, we note the 10-day average is 5.57 million shares, with the 3-month average coming to 1.64 million.
Analysts gave the Cabaletta Bio Inc (CABA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CABA as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Cabaletta Bio Inc’s EPS for the current quarter is expected to be -0.64.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cabaletta Bio Inc (NASDAQ:CABA) trade information
Instantly CABA is in green as seen in intraday trades today. With action 119.79%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -81.89%, with the 5-day performance at 119.79% in the green. However, in the 30-day time frame, Cabaletta Bio Inc (NASDAQ:CABA) is 15.77% up. Looking at the short shares, we see there were 3.71 million shares sold at short interest cover period of 4.26 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 70.64% from its recent market value. According to analyst projections, CABA’s forecast low is 3 with 32 as the target high. To hit the forecast high, the stock’s price needs a -678.59% plunge from its current level, while the stock would need to tank 27.01% for it to hit the projected low.
Cabaletta Bio Inc (CABA) estimates and forecasts
Data shows that the Cabaletta Bio Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -58.94% over the past 6 months, a -40.00% in annual growth rate that is considerably lower than the industry average of 17.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -26.63%. The 2024 estimates are for Cabaletta Bio Inc earnings to decrease by -40.16%.
CABA Dividends
Cabaletta Bio Inc is expected to release its next quarterly earnings report in January.
Cabaletta Bio Inc (NASDAQ:CABA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.10% of Cabaletta Bio Inc shares while 100.47% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.68%. There are 100.47% institutions holding the Cabaletta Bio Inc stock share, with JENNISON ASSOCIATES LLC the top institutional holder. As of 2024-06-30, the company held 11.2498% of the shares, roughly 5.55 million CABA shares worth $41.49 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.6469% or 4.76 million shares worth $35.58 million as of 2024-06-30.
